See the DrugPatentWatch profile for xphozah

Based on the provided sources, there is no specific information available regarding the projected or predicted peak sales period for XPHOZAH. The first source, DrugPatentWatch, provides information about the drug XPHOZAH but does not mention any sales projections or peak sales period [1]. The second source, the investor relations page of Ardelyx, provides information about the drug and its development but does not mention any sales projections or peak sales period [2]. The third source, the Centers for Medicare & Medicaid Services (CMS) website, provides information about the payment system for end-stage renal disease (ESRD) but does not mention XPHOZAH or any sales projections [3].

In conclusion, based on the provided sources, there is no available information regarding the projected or predicted peak sales period for XPHOZAH.

Sources:
[1] DrugPatentWatch. (n.d.). XPHOZAH. Retrieved from https://www.drugpatentwatch.com/p/tradename/XPHOZAH
[2] Ardelyx. (n.d.). Investor Relations. Retrieved from https://ir.ardelyx.com/static-files/a0743a58-6758-4a8b-bc59-f8f210ea40e4
[3] Centers for Medicare & Medicaid Services. (n.d.). End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). Retrieved from https://www.cms.gov/medicare/payment/prospective-payment-systems/end-stage-renal-disease-esrd